H

Herlev Hospital | Nephrology Department

Research site
(Unclaimed)
Location
Nyresygdomme Klinik 1, Borgmester Ib Juuls Vej 73. Entrance 8, 4th Floor, O1, Herlev, Hovedstaden, Denmark
Site insights

Top conditions

Prostatic Cancer (12 trials)

Kidney Diseases (11 trials)

Cancer (10 trials)

Colorectal Cancer (9 trials)

Breast Cancer (9 trials)

Top treatments

Docetaxel
Capecitabine
Trastuzumab
Oxaliplatin
capecitabine
Adalimumab
Melatonin
Upadacitinib
Lenalidomide
oxaliplatin

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

22 of 224
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433

A multicenter study to evaluate the efficacy and safety of maintenance and long-term treatment administration of upadacitinib, an orally administered...

Active, not recruiting
Crohn's Disease
Drug: Upadacitinib
Drug: Placebo for Upadacitinib

This study evaluates the combination of SCO-101 to FOLFIRI for the treatment of metastatic colorectal cancer patients who have developed resistance t...

Enrolling
Metastatic Colorectal Cancer
Drug: FOLFIRI Protocol
Drug: SCO-101

This is a phase III, randomized, open-label, multicenter trial, conducted in Sweden, Norway, Finland, Denmark, Italy, Australia and New Zealand, in e...

Enrolling
DLBCL
Diffuse Large B Cell Lymphoma
Drug: R-pola-mini-CHP
Drug: R-mini-CHOP

A study designed tocompare progression-free survival (PFS) in participants with t(11;14)-positive MM treated with venetoclax in combination with dexa...

Active, not recruiting
Multiple Myeloma
Drug: Dexamethasone
Drug: Pomalidomide

The purpose of this study is to evaluate whether milvexian compared to placebo reduce the risk of recurrent ischemic stroke.

Enrolling
Ischemic Stroke; Ischemic Attack, Transient
Drug: Placebo
Drug: Milvexian

The purpose of the study is to determine if the combination of niraparib with Abiraterone Acetate (AA) plus prednisone compared with AA plus predniso...

Active, not recruiting
Metastatic Castration-sensitive Prostate Cancer
Drug: Placebo for Niraparib
Drug: Niraparib

The purpose of the study is to evaluate the efficacy of olezarsen as compared to placebo on the percent change in fasting triglycerides (TG) from bas...

Enrolling
Severe Hypertriglyceridemia
Drug: Placebo
Drug: Olezarsen

The purpose of this study is to determine the effect of ixazomib citrate maintenance therapy on progression-free survival (PFS), compared to placebo,...

Active, not recruiting
Autologous Stem Cell Transplant
Multiple Myeloma
Drug: Ixazomib Citrate
Drug: Placebo

The purpose of this study is to determine how participants with metastatic castration-resistant prostate cancer, and evidence of a homologous recombi...

Active, not recruiting
Metastatic Castration Resistant Prostate Cancer
Drug: Abiraterone acetate or Enzalutamide or Docetaxel
Drug: Rucaparib

This study will evaluate the safety, tolerability, and pharmacokinetics of Runimotamab administered intravenously as a single agent and in combinatio...

Active, not recruiting
Solid Tumors
Drug: Runimotamab
Drug: Tocilizumab

This study is being done to see if tucatinib with ado-trastuzumab emtansine (T-DM1) works better than T-DM1 alone to help patients who have a specifi...

Enrolling
HER2-positive Breast Cancer
Drug: T-DM1
Drug: placebo

This is a Phase 1/2a, dose-escalation, multicenter, first-in-human, consecutive-cohort, open-label study of BI-1808, as a single agent and in combina...

Enrolling
Advanced Malignancies
Drug: Pembrolizumab (KEYTRUDA® ) 25 Mg/mL Solution for Injection
Drug: BI-1808

The study aims to investigate the effect of Philips Ambient Experience with specially designed paediatric content on the experience of pediatric pati...

Enrolling
Behavior
Anxiety
Behavioral: Ambient Experience

Evaluate the safety and efficacy of eftilagimod alpha in combination with pembrolizumab against pembrolizumab alone in 1st line metastatic or recurre...

Active, not recruiting
HNSCC
Drug: Pembrolizumab
Drug: Eftilagimod alpha

This open-label, multicenter, randomized Phase III study is designed to compare the efficacy and safety of a combined regimen of obinutuzumab and ven...

Active, not recruiting
Lymphocytic Leukemia, Chronic
Drug: Venetoclax
Drug: Obinutuzumab
Locations recently updated

The purpose of this study is to evaluate the safety and efficacy of the study drug abemaciclib in participants with high risk, node positive, early s...

Active, not recruiting
Breast Cancer
Drug: Abemaciclib
Drug: Standard Adjuvant Endocrine Therapy

The primary objective of this study is to evaluate the long-term safety and tolerability of efavaleukin alfa in participants with moderate to severe...

Enrolling
Ulcerative Colitis
Drug: Efavaleukin alfa
Drug: Placebo

The ProTarget study is a phase II, prospective, non-randomized clinical trial with the primary purpose of investigating the safety and efficacy of co...

Enrolling
Tumors
Neoplasia
Drug: Axitinib
Drug: Trastuzumab plus Pertuzumab (combination)

The main purpose of this study is to evaluate the effect of efavaleukin alfa on induction of clinical remission in participants with moderately to se...

Enrolling
Ulcerative Colitis
Drug: Placebo
Drug: Efavaleukin alfa

An international, multicenter, open-label, 2 cohort, non-comparative, pivotal study evaluating the efficacy of tipifarnib in HRAS mutant HNSCC (AIM-H...

Active, not recruiting
HNSCC
HRAS Gene Mutation
Drug: Tipifarnib
Device: HRAS Detection Assay

Trial sponsors

H

Herlev Hospital (37 trials)

AbbVie logo

AbbVie (12 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems